Tavneos (Avacopan)
avacopan 10 mg capsule, 180 · ORAL · PBS code 14605Q
AUTHORITY_REQUIREDWhat it costs
AU$8323.2 PBS-determined price per 180 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-10-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis
Induction treatment
The condition must be severe granulomatosis with polyangiitis; or
The condition must be severe microscopic polyangiitis; AND
The condition must be active at the time of the first prescription for this drug per treatment cycle; AND
Patient must have ANCA associated vasculitis that is either: (i) organ-threatening, (ii) life-threatening disease; AND
Patient must be undergoing concomitant therapy with at least another drug therapy as part of a regimen specified in this drug's approved Product Information; AND
Patient must not receive more than 12 months of PBS-subsidised treatment with this drug per induction.
A prescriber may apply for more than one induction treatment for their patient
Sponsor: Seqirus (Australia) Pty Ltd ABN 66 120 398 067
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.